ProKidney (PROK) Revenue & Revenue Breakdown
ProKidney Revenue Highlights
00
ProKidney Revenue by Period
ProKidney Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
ProKidney Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $4.49M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | - |
ProKidney Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
IMCR | Immunocore | $249.43M | $75.40M |
ACLX | Arcellx | $110.32M | $26.03M |
ARVN | Arvinas | $78.50M | $102.40M |
PTGX | Protagonist Therapeutics | $60.00M | $4.67M |
MRUS | Merus | $43.95M | $11.77M |
RLAY | Relay Therapeutics | $25.55M | - |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
PLRX | Pliant Therapeutics | $1.58M | - |
LYEL | Lyell Immunopharma | $130.00K | $34.00K |
BDTX | Black Diamond Therapeutics | - | - |
PCVX | Vaxcyte | - | - |
DICE | DICE Therapeutics | - | - |
CERE | Cerevel Therapeutics | - | - |
REPL | Replimune Group | - | - |
KURA | Kura Oncology | - | - |
ERAS | Erasca | - | - |
VTYX | Ventyx Biosciences | - | - |
PMVP | PMV Pharmaceuticals | - | - |
PROK | ProKidney | - | - |
THRD | Third Harmonic Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
ENOB | Renovaro Biosciences | - | - |
EWTX | Edgewise Therapeutics | - | - |